Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
When women and their doctors talk about “hormone therapy” they are most commonly referring to the (now) highly controversial issue of whether hormonal supplements (estrogen and progesterone) should be used at and after menopause to prevent the symptoms of menopause and/or later risks related to heart disease and osteoporesis. … READ MORE …
Filed under: Management, Treatment | Tagged: androgen deprivation, castration, definition, hormone therapy, medical, surgical | 21 Comments »
Today at the ASCO annual meeting, Maha Hussein presented the results a long-term, international, randomized trial of intermittent androgen deprivation (IAD) versus continuous androgen deprivation (CAD) in men with hormone-sensitive, metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: androgen deprivation, continuous, hormone therapy, intermittent, outcome, survival | 5 Comments »
A new article in the journal Anticancer Research suggests that patients had greater satisfaction after modern forms of external beam radiation therapy (EBRT) than after some other standard forms of first-line treatment. Of course the absolute truth of this conclusion may be affected by the details of the study. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: brachytherapy, external beam, hormone therapy, outcome, patient, radiation therapy, satisfaction, surgery | 1 Comment »
New data published by clinical researchers at the Mayo Clinic have suggested that there is no overall survival benefit associated with adjuvant hormone therapy after surgery in men with pathological T3b disease. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, ADT, hormone therapy, post-surgery, pT3b | 9 Comments »
The Irish Clinical Oncology Research Group trial 97-01 was a randomized clinical trial designed to compare the long-term outcomes of patients treated with either 4 months or 8 months of hormonal therapy given before external beam radiotherapy for localized prostate cancer. … READ MORE …
Filed under: Management, Treatment | Tagged: EBRT, external beam radiation therapy, hormone therapy, neoadjuvant, outcome | Leave a Comment »
In the late 1980s and early 1990s it was generally considered that men diagnosed with metastatic (but still hormone sensitive) prostate cancer had an estimated survival of 18 to 36 months from the time of diagnosis — including their time on treatment with hormonal therapy. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CRPC, hormone therapy, mCRPC, survival | 6 Comments »
There were a number of significant prostate cancer presentations today, and while none of them were “game changing” (for a variety of reasons), they are certainly worthy of notice. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, bevacizumab, cabazitaxel, external beam radiation, hormone therapy | 2 Comments »
Many patients with no specific evidence of metastatic disease now receive primary androgen deprivation therapy (PADT) much earlier than was the case before the availability of the PSA test. This includes patients who get hormone therapy for a rising PSA after other forms of first-line therapy and patients who receive hormone therapy as their first-line treatment. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation therapy, hormone therapy, primary | 4 Comments »
An article in just published in Onkologie reports the diagnosis and (short-term) treatment of widely disseminated, metastatic prostate cancer in a 64-year-old Croatian man with a PSA of > 21,000 ng/ml. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: hormone therapy, PSA, survival, timing | 4 Comments »
The RTOG 94-08 clinical trial was designed to test the idea that just 4 months of hormone therapy, administered before and during radiation therapy, would improved the overall survival of patients diagnosed with clinical stage T1b-T2b prostate cancer and a PSA level equal to or lower than 20 ng/ml. … READ MORE …
Filed under: Management, Treatment | Tagged: external beam radiation therapy, hormone therapy, localized disease, RTOG 94-08, survival | 1 Comment »
In this weekend’s prostate cancer news reports, we have addressed recent publications on:
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: African American, age, biopsy, brachytherapy, diabetes, focal, hormone therapy, mortality, neoadjuvant, obesity, race, single nucleotide polymorphism, SNP, Treatment | Leave a Comment »
Today’s news reports summarize papers recently published on:
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", estradiol, hormone therapy, HRQOL, optimism, outcomes, paclitaxel, pessimism, quality of life, radiation, radical prostatectomy | Leave a Comment »
A report presented yesterday in Chicago, at the annual meeting of the American Society for Radiation Oncology (ASTRO), suggests that short-term hormone therapy given prior to and during first-line radiation treatment to intermediate-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation alone. However, the same study also showed that there is no significant benefit for low-risk patients. … READ MORE …
Filed under: Management, Treatment | Tagged: first line, hormone therapy, localized, radiation, RTOG 94-08 | Leave a Comment »
Today’s news reports cover items on:
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, androgen deprivation, biopsy, cardiovasular, castration-resistant prostate cancer, complete, CRPC, hormone therapy, intermittent, marker, protocol, side effects, surrogate | Leave a Comment »
A recent report in the International Journal of Radiation Oncology • Biology • Physics suggests that the type of hormone therapy used in combination with brachytherapy for treatment of localized prostate cancer makes no difference to the patients’ long-term outcomes. … READ MORE …
Filed under: Management, Treatment | Tagged: brachytherapy, hormone therapy, outcomes | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site